Company Gets Grants from the Michael J. Fox Foundation for Parkinson’s Research and from the Department of Defense.

LEXINGTON, KY. and NEW YORK, NY. (June 16, 2022) – Gismo Therapeutics Inc. has been awarded two new grants to continue development of therapies to treat Parkinson’s Disease and Amyotrophic Lateral Sclerosis (ALS). A $280,000 grant entitled “A Novel Preclinical Development Candidate for the Treatment of Parkinson’s Disease” has been received from The Michael J. Fox Foundation for Parkinson’s Research, from its Therapeutic Pipeline Program. A $618,000 grant entitled “A Novel Therapeutic Approach for Targeting TDP-43 in ALS” has been received from the Congressionally Directed Medical Research Programs (CDMRP) administered by the Department of Defense.

About Gismo Therapeutics Inc.:

Gismo Therapeutics Inc. is a biotech start-up company targeting fundamental biochemical processes that are at the root cause of amyloid neurodegenerative diseases pathogenesis. The company is developing its pioneering technology, GISMO, which is associated with a new hypothesis of the etiology of major neurodegenerative diseases. Gismo Therapeutics Inc. is developing first-in-class, disease modifying oral therapeutics for the treatment of Alzheimer’s and Parkinson’s Disease and ALS. Gismo Therapeutics Inc. was incorporated in Delaware and has offices in Lexington, Kentucky and Queens, New York. The company is privately held and supported by grants from the NIH and the Kentucky Cabinet for Economic Development, and by private funding. The company was founded by Paul Gregor, Ph.D., CEO, a graduate of the Weizmann Institute of Science (Rehovot, Israel). Its Scientific Advisory Board includes Dennis Choi, M.D., Ph.D., an award-winning neurologist, Chair of Department of Neurology and Director of the Neuroscience Institute, Stony Brook University, New York, and Prof. Bruce F. O’Hara, Ph.D., Department of Biology, University of Kentucky, Lexington, KY.

For more information about Gismo Therapeutics Inc., visit the company’s website, www.gismotherapeutics.com.

Contact:
Dr. Paul Gregor
Tel: (347) 233-2037
e-mail: informa@gismotherapeutics.com